Cancer patient finds hope – and remission – in CAR T cell therapy
When the U.S. Food and Drug Administration (FDA) announced its approval of a new immunotherapy in August 2017, it was a breakthrough for precision medicine. The immunotherapy – used to treat a form of pediatric leukemia – became the first FDA-approved, commercially available chimeric antigen receptor T-cell (CAR T) therapy.
The therapy uses Cell Therapy Systems (CTS) Dynabeads technology, developed by Thermo Fisher, to activate and expand T cells that have been genetically engineered to recognize and fight cancers unique to each patient. This all starts with the patient’s own cells, which are infused back into them after the process is complete.
Nicole Gularte’s cells took this journey, and today she remains cancer free. But her road was far from easy. After being diagnosed with acute lymphoblastic leukemia (ALL) in 2010, and spending the next six years in and out of treatment, this novel precision medicine approach was her last hope: She had exhausted all other options.
Learn more about Nicole’s story in the video below.